Why PROCEPT BioRobotics (PRCT) Dropped -15%: When a High‑Growth Med‑Tech Misfires on Revenue and Resets Its 2026 Roadmap
PROCEPT BioRobotics Corp (PRCT) fell more than 15% today after it reported a sizable Q4 revenue and earnings miss, cut its 2026 revenue guidance, and signaled near‑term sales disruption from changes to its commercial model and sales organization.
Key Takeaways
-
Q4 2025 revenue was about 76.4 million dollars, growing ~12% year over year but missing consensus by roughly 18–19% (Street around 94–96 million dollars).
-
The company posted a larger‑than‑expected loss of about 0.53 dollars per share, versus expectations for a loss near 0.32 dollars, as operating losses widened.
-
Management cut 2026 revenue guidance from 410–430 million dollars to 390–410 million dollars, even as they reiterated a long‑term path to profitability and high‑60s gross margins.
-
Several brokers, including BofA and Wells Fargo, lowered price targets (and in BofA’s case, downgraded to Underperform), citing the Q4 shortfall, weaker guidance, and growing operating losses.
-
The stock slid to a new 52‑week low and is now trading well below key moving averages, reflecting shaken confidence in execution despite still‑strong procedure growth and a large addressable market.
What Went Wrong in Q4?
On the surface, PRCT’s top line still grew: Q4 2025 revenue reached about 76.4 million dollars, up roughly 11.9–12% from the prior year. However, analysts had expected something closer to 94–96 million dollars, so the shortfall of nearly 20% was significant for a high‑growth med‑tech name.
Management attributed the miss mainly to two self‑inflicted factors: a restructuring of the sales force and a strategic change in how it manages customer handpiece inventory and bulk purchase discounts. The reorganization temporarily reduced field experience and slowed deal flow, while the shift away from heavy upfront discounting pulled some revenue out of Q4 and into future periods.
On profitability, the picture also deteriorated. The Q4 net loss widened to about 29.8 million dollars (around 0.53 dollars per share), up from an 18.9 million dollar loss a year earlier, as operating expenses outpaced revenue growth and gross margin slipped from roughly 64% to about 61%, partly due to lower‑than‑expected U.S. consumables revenue and a one‑time voluntary field‑action expense.
Guidance Reset and Wall Street’s Reaction
The company now expects 2026 revenue of 390–410 million dollars, down from its prior range of 410–430 million dollars, and is guiding to about 65% gross margin in 2026 with a target of 68–70% in 2027 as scale and mix improve. While that still implies solid growth, it is clearly below what the market had been pricing in, especially after a long run‑up on the Aquablation growth story in BPH and potential future expansion into prostate cancer.
In response, BofA cut its rating from Neutral to Underperform and slashed its price target from 38 to 20 dollars, citing the magnitude of the Q4 miss, the guidance cut, and the fact that operating losses are becoming more negative, which undermines valuation support. Wells Fargo also lowered its target (to 34 dollars from 51) while keeping an Overweight rating, but acknowledged that the “second‑half‑weighted” guide and commercial disruption make the near term choppier.
Traders reacted quickly: shares fell more than 20% intraday, hit a new 52‑week low around the low‑20s, and now trade at roughly 2x updated 2026 sales—near the low end of small‑ and mid‑cap med‑tech peers—showing how sharply sentiment has reversed, at least in the short term.
Growth Story Intact, But Execution in Question
Despite the sell‑off, the underlying clinical and market story has not disappeared. PRCT delivered record procedure volumes in Q4 (about 12,200 Aquablation procedures) and sold 65 new systems, marking its strongest capital quarter to date and suggesting that physician and hospital adoption remains robust. The company also continues to point to a large underpenetrated BPH market and sees a potential upside vector in prostate cancer, which some analysts argue is not yet fully reflected in the stock price.
However, today’s move shows that investors are no longer willing to overlook execution stumbles, growing losses, and guidance resets in exchange for a long‑dated growth promise. Until the company proves it can deliver on its updated 2026 outlook, stabilize its sales organization, and move meaningfully toward breakeven, the stock is likely to trade with a discount for execution risk—hence the sharp 15%+ drop you see today.
Tickeron AI Perspective
Contributor
Advertisement